immatics’ vaccine increases survival in kidney cancer
July 30, 2012Research and Development, Sales and Marketing IMA901, Vaccine, Yervoy, immatics, phase III
immatics’ investigational cancer vaccine has increased survival rates in patients with renal cell carcinoma. In a late-stage trial, the German …
J&J expects consent decree to extend through ‘most of 2013’
July 30, 2012Manufacturing and Production FDA, J&J, JJ, McNeil, OTC, recall
Johnson & Johnson has said it expects the production capacity issues affecting two plants covered by a consent decree with …
Prevenar 13 rejected for UK vaccination programme
July 27, 2012Sales and Marketing JCVI, Pfizer, Pneumovax, Sanofi Pasteur, prevenar 13
The UK’s joint committee on vaccination and immunisation is recommending against a switch to Pfizer’s pneumococcal vaccine Prevenar 13 from …
IT problems at Swedish plant affect AstraZeneca
July 27, 2012Manufacturing and Production AstraZeneca, Nexium, Symbicort, financials
Software problems at a manufacturing facility operated by AstraZeneca in Sweden are having a material impact on the business, pegging …
Roche posts strong sales results
July 27, 2012Sales and Marketing Pegasys, Perjeta, Roche, Zelboraf, dalcetrapib
Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …
Acting chair of Public Health England appointed
July 26, 2012Sales and Marketing David Heymann, Public Health England
David Heymann has been appointed as the acting chair of Public Health England. Dr Heymann, currently chairman of the Health …
AstraZeneca’s Fluenz chosen for wider flu immunisation
July 26, 2012Sales and Marketing AZ, AstraZeneca, Cervarix, Gardasil, Lansley, MedImmune
The UK has chosen AstraZeneca’s Fluenz to extend the country’s flu vaccination programme. The health secretary Andrew Lansley said that …
AstraZeneca sees big sales drop in Q2
July 26, 2012Sales and Marketing AstraZeneca, Brennan, Brilinta, Q2, Seroquel
AstraZeneca has today reported a large drop in revenue for the second quarter. The firm has been hit by major …
Janssen launches drug reminder service ‘Care4Today’
July 26, 2012Medical Communications Care4Today, Janssen, digital
Janssen has launched a new digital service designed to help patients remember to take their medication. Care4Today Mobile Adherence is …
The fight over ‘Obamacare’ goes on
July 26, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Medicaid, Obama, Obamacare, Romney, US, healthcare
The recent ruling by the US Supreme Court which upheld President Obama’s healthcare reforms could save the country around $84 …
Life appoints senior copywriter
July 26, 2012Medical Communications Elinor Washbrook, Life
Life Healthcare Communications has appointed a new senior copywriter to develop its creative team. Elinor Washbrook joins Life with over …
Lucentis price cut ends PCT-Novartis dispute
July 26, 2012Sales and Marketing ABPI, NHS, PCTs, Roche, SHIP Cluster, avastin
An NHS body has been persuaded to reverse its policy of recommending Avastin for wet AMD. The Southampton, Hampshire, Isle …
NHS Commissioning Board appoints key directors
July 26, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ann Sutton, Lyn Simpson, NHS Commissioning, PCT
The NHS Commissioning Board Authority has announced the appointment of the two director posts in the national leadership team of …
GSK falters in Q2 as austerity measures bite
July 25, 2012Sales and Marketing Benylsta, GSK, Q2, Seretide, Witty
GlaxoSmithKline posted a loss in its second quarter results, as pressure in mature markets continues to affect the firm. Pharmaceutical …
Europe looking to revamp clinical trial laws
July 25, 2012Research and Development, Sales and Marketing EFPIA, EU, Europe, clinical trials
The European Commission has put forward new proposals aimed at revamping clinical trial laws. The legislation will replace rules that …
FDA approves Forest’s COPD drug
July 25, 2012Sales and Marketing COPD, FDA, Forest, Tudorza Pressair
US regulators have approved Forest Laboratories’ new chronic obstructive pulmonary disease (COPD) drug. Tudorza Pressair (aclidinium bromide) has been given …
Parexel’s BioPharm Unit to aid smaller R&D firms
July 25, 2012Research and Development Parexel, R&D, biotech
Parexel has launched the Parexel BioPharm Unit – a new division focused on the needs of small and mid-sized biopharma …
ADMA Biologics appoints Lawrence Guiheen to board of directors
July 25, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing ADMA Biologics, Lawrence Guiheen
Late-stage biotech firm ADMA Biologics has announced it has appointed Lawrence Guiheen to its board of directors. Guiheen said: “Having …
Physios and podiatrists to gain new prescribing powers
July 25, 2012Sales and Marketing Department of Health, GPs, Physios, government, prescribing
Physiotherapists and podiatrists are set to gain new prescribing powers by 2014. Ministers are looking to amend medicines legislation so …
NICE yes for Xarelto to treat blood clots
July 25, 2012Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto
NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
